Abstract:The genetic basis of antipsychotic drug efficacy is likely polygenic in nature. Genetic risks of schizophrenia may also be related to antipsychotic drug response. The Psychiatric Genomics Consortium (PGC) Genome-Wide Association Study (GWAS) provided evidence of association with schizophrenia risk for many Single Nucleotide Polymorphism (SNP) across the genome. We examined whether Polygenic Risk Scores (PRS) based on the PGC GWAS are predictive of antipsychotic efficacy in four cohorts of patients with first episode psychosis (total n=510): 1) Zucker Hillside Hospital First Episode schizophrenia trial (ZHH-FE), 2) European First Episode Schizophrenia Trial (EUFEST), 3) Spanish First Episode Psychosis study (SFEP), and 4) the clinical trial as part of the Center for Intervention Development and Applied Research at ZHH (CIDAR). The discovery cohort was the ZHH-FE with 77 patients (mixed ethnicity) randomized to risperidone or olanzapine. Three replication cohorts were: 1) EUFEST with 141 patients (all Caucasian) randomized to five antipsychotics; 2) SFEP with 192 patients (all Caucasian) on various antipsychotics; and 3) CIDAR with 100 patients (mixed ethnicity) randomized to risperidone or aripiprazole. Genotyping was performed using the Illumina Omni-1Quad (EUFEST and ZHH-FE) or Illumina Infinium HumanOmniExpressExome platform (CIDAR and SFEP). SNP imputation was conducted with IMPUTE2 against the full 1000 Genomes v3 reference panel. PRS was computed based on the results of the PGC GWAS using PRSice software for the discovery cohort with thresholds at PT<5E-8, 0.001, 0.01, 0.05, 0.10, 0.20, 0.50. Based on the findings from the discovery cohort, PRS was computed for the three replication cohorts using a threshold of PT<0.01. Symptom measure was the total score of Brief Psychiatric Rating Scale (BPRS) for ZHH-FE, SFEP, and CIDAR, or Positive and Negative Symptoms Scale (PANSS) for EUFEST. Hierarchical linear regression was performed on the 3-month symptom score with the PRS as the predictor while controlling for age, sex, and baseline symptom score. Genomic principal component scores were also covaried to control for population stratification for ZHH-FE and CIDAR. In the ZHH-FE cohort, higher PRS at the thresholds of PT<0.01, 0.05, 0.10, 0.20, and 0.50 significantly predicted higher symptom scores at 3-month follow-up, explaining 6–8% of the variance (all p's<0.05). PT<0.01 gave the strongest result in the discovery sample, and was used to replicate the findings in the other three cohorts. Higher PRS significantly predicted worse symptoms in EUFEST and SFEP cohorts, explaining 3.5% and 3.7% of variance, (p's<0.01), but not in the CIDAR sample. Combining the four cohorts in a meta-analysis, PRS was significantly predictive of 3-month symptom scores (pooled partial r=0.18, p=0.002). Higher PRS was associated with higher symptom scores at 3-month follow-up, suggestive of less improvement in treatment. The overall results remained significant when only European ancestry individuals were included in the analysis. These findings suggest that polygenic risk scores for schizophrenia may also be related to antipsychotic drug response. Patients with higher polygenic risk scores tended to have less improvement with antipsychotic drug treatment. Further analysis is needed to elucidate a more refined genomic profile for antipsychotic drug response.

New Role of Platelets in Schizophrenia: Predicting Drug Response

Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia.

The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia.

Baseline Platelet Count and Clinical Outcome in Acute Coronary Syndrome

Association of Telomere Length and Mitochondrial DNA Copy Number with Risperidone Treatment Response in First-Episode Antipsychotic-Naïve Schizophrenia

Elevated Platelet Parameter in First-Episode Schizophrenia Patients: A Cross-Sectional Study

Platelet haemostatic function in psychiatric disorders: Effects of antidepressants and antipsychotic drugs

Diminished treatment response in relapsed versus first-episode schizophrenia as revealed by a panel of blood-based biomarkers: A combined cross-sectional and longitudinal study

The effects of quetiapine and aripiprazole on platelet 5-HT concentrations in patients with schizophrenia

[Platelet activity in the chronic schizophrenic patients during attacks outcome and remission development]

State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia

Short-term Effects of Antipsychotic Treatment on Cerebral Function in Drug-Naive First-Episode Schizophrenia Revealed by “resting State” Functional Magnetic Resonance Imaging

In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation

The activity of platelet enzymes and subpopulation composition of monocytes in schizophrenia

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia

Hematological and inflammatory markers in Han Chinese patients with drug-free schizophrenia: relationship with symptom severity

Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction

Baseline serum vascular endothelial growth factor levels predict treatment response to antipsychotic medication in patients with schizophrenia.

SCHIZOPHRENIA POLYGENIC RISK SCORE PREDICTS ANTIPSYCHOTIC TREATMENT RESPONSE IN PATIENTS WITH FIRST EPISODE PSYCHOSIS

The Role of Cytokines in Predicting the Efficacy of Acute Stage Treatment in Patients with Schizophrenia

Association of Complement and Coagulation Pathway Proteins with Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial